Harry Jr. Thomasian Purchases 2,932 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian purchased 2,932 shares of the business’s stock in a transaction dated Friday, September 26th. The stock was bought at an average cost of $3.42 per share, with a total value of $10,027.44. Following the completion of the acquisition, the chief financial officer owned 468,626 shares of the company’s stock, valued at approximately $1,602,700.92. The trade was a 0.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Harry Jr. Thomasian also recently made the following trade(s):

• On Thursday, September 25th, Harry Jr. Thomasian purchased 8,284 shares of Precigen stock. The shares were bought at an average price of $3.62 per share, for a total transaction of $29,988.08.

Precigen Stock Up 0.9%

PGEN opened at $3.51 on Friday. Precigen, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $5.22. The business has a fifty day simple moving average of $3.11 and a 200-day simple moving average of $2.06. The firm has a market cap of $1.05 billion, a PE ratio of -8.36 and a beta of 1.82.

Precigen (NASDAQ:PGEN) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%. On average, equities research analysts anticipate that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on PGEN. JPMorgan Chase & Co. raised shares of Precigen from an “underweight” rating to a “neutral” rating in a research report on Friday, August 15th. Wall Street Zen raised Precigen from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. JMP Securities boosted their price objective on Precigen from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 19th. HC Wainwright reiterated a “buy” rating and set a $8.50 target price on shares of Precigen in a research note on Tuesday, August 19th. Finally, Citigroup reissued an “outperform” rating on shares of Precigen in a research report on Tuesday, August 19th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.25.

Institutional Trading of Precigen

A number of large investors have recently bought and sold shares of PGEN. BNP Paribas Financial Markets bought a new position in Precigen during the 4th quarter worth $27,000. Apella Capital LLC bought a new position in Precigen in the 1st quarter worth $40,000. Voya Investment Management LLC grew its holdings in Precigen by 142.9% during the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 21,633 shares during the last quarter. ProShare Advisors LLC lifted its position in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 10,900 shares during the last quarter. Finally, Strs Ohio acquired a new stake in shares of Precigen in the first quarter valued at about $70,000. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.